Skip to main content
SpringerLink
Log in

Suppressive effect upon carboplatin hypersensitivity reaction via pegylated liposomal doxorubicin combination therapy

  • Original Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Background

Occurrence of hypersensitivity reaction (HSR) in patients having received multiple doses of carboplatin has been reported. Several studies demonstrated reduction of carboplatin-associated HSR with in combination with pegylated liposomal doxorubicin (PLD). The objective of this study was to determine the suppressive effect on carboplatin-induced HSR via combined treatment with PLD within clinical practice.

Methods

We reviewed the medical records of women with primary or recurrent ovarian, fallopian tube, or peritoneal cancer treated with carboplatin containing regimen at our hospital between January 2009 and March 2019. We compared the incidence of carboplatin-induced HSR among patients who received more than one cycle of PLD plus carboplatin (PLD-C) therapy (i.e., PLD-C group) versus patients who never received PLD-C therapy (non-PLD-C group).

Results

A total of 414 women were included in this study (48: PLD-C group, 366: non-PLD-C group). Carboplatin-induced HSR occurred in 34 total patients (8.2%) [1/48 (2.1%) in the PLD-C group and 33/366 (9.0%) in the non-PLD-C group], with a median cycle number of carboplatin administration at onset of HSR being 9. Incidences of carboplatin-induced HSR within the PLD-C versus non-PLD-C group at the 8th, 12th, and 16th cycles of carboplatin administration were 2.2% vs 11.2%, 2.2% vs 28.6%, and 2.2% vs 39.1%, respectively [hazard ratio: 19.2 (95% confidence interval: 9.82–39.4), p < 0.0001].

Conclusion

Based on the data analyzed here, a suppressive effect on carboplatin-induced HSR via combination therapy with PLD was confirmed within clinical practice.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Ozols RF, Bundy BN, Greer BE et al (2003) Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 21:3194–3200

    Article  CAS  Google Scholar 

  2. Bookman MA, Brady MF, McGuire WP et al (2009) Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol 27:1419–1425

    Article  CAS  Google Scholar 

  3. Markman M, Kennedy A, Webster K et al (1999) Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol 17:1141–1145

    Article  CAS  Google Scholar 

  4. Schwartz JR, Bandera C, Bradley A et al (2007) Does the platibum-free interval predict the incidence or severity of hypersensitivity reactions to carboplatin? The experience from Women and Infants’ Hospital. Gynecol Oncol 105:81–83

    Article  CAS  Google Scholar 

  5. Navo M, Kunthur A, Badell ML et al (2006) Evaluation of the incidence of carboplatin hypersensitivity reactions in cancer patients. Gynecol Oncol 103:608–613

    Article  CAS  Google Scholar 

  6. Zanotti KM, Rybicki LA, Kennedy AW et al (2001) Carboplatin skin testing: a skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy. J Clin Oncol 19:3126–3129

    Article  CAS  Google Scholar 

  7. Joly F, Ray-Coquard I, Fabbro M et al (2011) Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: analysis from the GCIG CALYPSO relapsing ovarian cancer trial. Gynecol Oncol 122:226–232

    Article  CAS  Google Scholar 

  8. Park SJ, Kim J, Kim HS et al (2020) Real world effectiveness and safety of pegylated liposomal doxorubicin in platinum-sensitive recurrent ovarian, fallopian, or primary peritoneal cancer: a Korean multicenter retrospective cohort study. J Gynecol Oncol 31(2):e15

    Article  Google Scholar 

  9. Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E et al (2010) Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol 28:3323–3329

    Article  CAS  Google Scholar 

  10. Lenz HJ (2007) Management and preparedness for infusion and hypersensitivity reactions. Oncologist 12:601–609

    Article  CAS  Google Scholar 

  11. Markman M, Moon J, Wilczynski S et al (2010) Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trial. Gynecol Oncol 116(3):323–325

    Article  CAS  Google Scholar 

  12. Fujiwara H, Ushijima K, Nagao S et al (2019) A phase II randomized controlled study of pegylated liposomal doxorubicin and carboplatin vs. gemcitabine and carboplatin for platinum-sensitive recurrent ovarian cancer (GOTIC003/intergroup study). Int J Clin Oncol 24(10):1284–1291

    Article  CAS  Google Scholar 

  13. Banerji A, Lax T, Guyer A et al (2014) Management of hypersensitivity reactions to carboplatin and paclitaxel in outpatient oncology infusion center: a 5-year review. J Allergy Clin Immunol Pract 2:428–433

    Article  Google Scholar 

  14. Makrilia N, Syrigou E, Kaklamanos I et al (2010) Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review. Met Based Drugs 20:207084

    Google Scholar 

  15. Tai YH, Tai YJ, Hsu HC et al (2017) Risk factors of hypersensitivity to carboplatin in patients with gynecologic malignancies. Front Pharmacol 8:800

    Article  Google Scholar 

  16. Clamp AR, James EC, McNeish IA et al (2019) Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Lancet 394(10214):2084–2095

    Article  CAS  Google Scholar 

  17. Harris JM, Martin NE, Modi M (2001) Pegylation: a novel process for modifying pharmacokinetics. Clin Pharmacokinet 40(7):539–551

    Article  CAS  Google Scholar 

  18. Koide H, Asai T, Hatanaka K et al (2010) T cell-independent B cell response is responsible for ABC phenomenon induced by repeated injection of pegylated liposomes. Int J Pharm 392:218–223

    Article  CAS  Google Scholar 

  19. LaVigne K, Hyman DM, Zhou QC et al (2018) A randomized trial of prophylactic extended carboplatin infusion to reduce hypersensitivity reactions in recurrent ovarian cancer. Int J Gynecol Cancer 28(6):1176–1182

    Article  Google Scholar 

Download references

Funding

We have no funding about this study.

Author information

Authors and Affiliations

  1. Department of Gynecologic Oncology, Hyogo Cancer Center, 13-70 Kitaoji-cho, Akashi-city, Hyogo, 673-8558, Japan

    Kyoko Shimada, Shoji Nagao, Kazuhiro Suzuki, Takashi Shibutani, Kasumi Yamamoto, Tomoatsu Jimi, Hiroko Yano, Miho Kitai, Takaya Shiozaki & Satoshi Yamaguchi

Authors
  1. Kyoko Shimada
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shoji Nagao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kazuhiro Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Takashi Shibutani
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kasumi Yamamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Tomoatsu Jimi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hiroko Yano
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Miho Kitai
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Takaya Shiozaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Satoshi Yamaguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

SN designed the study. KS and SN collected and analyzed the data, and wrote the first draft of the manuscript. All authors contributed to data interpretation, reviewed the draft, and approved the final version of this report.

Corresponding author

Correspondence to Shoji Nagao.

Ethics declarations

Conflict of interest

None of the authors report a conflict of interest.

Ethical approval

All procedures related to this study were in accordance with the 1964 Helsinki Declaration and its later amendments.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shimada, K., Nagao, S., Suzuki, K. et al. Suppressive effect upon carboplatin hypersensitivity reaction via pegylated liposomal doxorubicin combination therapy. Int J Clin Oncol 25, 1718–1725 (2020). https://doi.org/10.1007/s10147-020-01706-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-020-01706-w

Keywords

Search

Navigation